Skip to content

Adult Onset Asthma: the first 5 years.

Adult Onset Asthma: the first 5 years.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON22527
Enrollment
200
Registered
2009-06-04
Start date
2009-06-22
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult onset asthma Severe asthma Phenotyping Markers

Interventions

None listed

Sponsors

Amsterdam Medical Centre, department of pulmonology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age between 18-75 years; 2. Physicians diagnosis of asthma after age of 18; 3. Physicians diagnosis of asthma >1 year prior enrolment; 4. Documented reversibility in FEV1>12% and 200 ml or Airway hyperresponsiveness to inhaled methacholine (PC2020% (with twice daily reading >10%).

Exclusion criteria

Exclusion criteria: 1. Smoking history >10py and a fixed airflow obstruction (FEV1 12% and 200ml; 2. Pregnancy; 3. Physician's diagnosis of asthma in childhood; 4. Other pulmonary diseases or non related major co-morbidities; 5. Diffusion capacity (TLCO/VA) <80%; 6. Episodes of dyspneu or multiple use of inhalde pulmonary medication in childhood (5-12yr).

Design outcomes

Primary

MeasureTime frame
Studie 1: Characterizing patients with adult onset asthma with respect to clinical, functional and inflammatory parameters. Subtypes will be defined by cluster analysis; risk factors of disease and poor quality of life will be defined. Studie 2: Clinical, functional and inflammatory parameters will be compared between 100 patients with recent onset asthma (1-5yr) and 100 patients with longstading adult onset asthma (>5yr). Studie 3: Three well defined subtypes will be compared by measurements of small airway function and sputum cells.

Contacts

Public ContactM. Amelink
m.amelink@amc.uva.nl+31 (0)20 5661660

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)